Its investigative team nearly in place, Vancouver-based Lexington Biosciences Inc. will shortly begin enrolling volunteers in a pilot study to test the Heartsentry device. The device measures the viability of the endothelium, those cells lining our arteries and critical to the prevention of atherosclerosis, heart attack and stroke.